| abstract |
The present invention relates to a novel neuropeptide Y analogue, a pharmaceutical composition comprising the same, a pharmaceutical formulation comprising the same, and a method of treating a disease or condition mediated by the binding of a neuropeptide Y-receptor. More particularly, the present invention relates to a neuropeptide Y1 receptor subtype, which selectively binds to the neuropeptide Y1 receptor subtype as compared to the neuropeptide Y2 receptor subtype, wherein the neuropeptide Y2 receptor subtype has proline substitution and other substitution (s) at position 34 as defined herein. And to a novel neuropeptide Y analogue. |